Know Cancer

or
forgot password

A Direct Comparison of Contrast Enhanced Power Doppler Ultrasound in Primary Breast Cancer and Axillary Nodal Status With Histopathological Variables and Clinical Outcome


N/A
18 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

A Direct Comparison of Contrast Enhanced Power Doppler Ultrasound in Primary Breast Cancer and Axillary Nodal Status With Histopathological Variables and Clinical Outcome


OBJECTIVES: I. Measure blood flow of primary breast lesions and corresponding lymph nodes by
Power Doppler Ultrasound (PDU) and compare this information with metastatic potential and
patient survival in women with primary breast cancer. II. Correlate intratumor/-nodal blood
flow with pathological variables using standard histology and special stains in this patient
population. III. Correlate intratumor microvessel density with total tumor blood flow and
with the presence of axillary lymph node metastases using this diagnostic method in these
patients. IV. Correlate tumor blood flow with various markers of angiogenesis using this
diagnostic method in these patients. V. Compare tumor blood flow as measured with PDU before
and after contrast enhancement in these patients.

OUTLINE: This is a diagnostic study. Patients receive ultrasound contrast agent IV. An
ultrasound probe with Power Doppler facility is swept over the skin surface in a standard
fashion before and after contrast enhancement. Blood flow data is acquired over the volume
of the mass and/or lymph nodes using a video recorder. The scanning time ranges between 5 to
15 minutes depending on the size and exact location of the breast mass and axillary lymph
nodes. Within 1 week of the ultrasound, patients undergo surgery and the mass and axillary
lymph nodes are removed.

PROJECTED ACCRUAL: Approximately 200 patients will be accrued for this study within 1 year.

Inclusion Criteria


DISEASE CHARACTERISTICS: Clinically suspected locally advanced breast cancer where
treatment indicated is primary surgery (wide local excision or simple mastectomy) and
axillary dissection (clearance) Inflammatory breast cancer eligible No recurrent disease
Hormone receptor status: Not specified

PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified
Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not
specified Hepatic: Not specified Renal: Not specified Cardiovascular: No New York Heart
Association class III or IV heart disease At least 14 days since prior myocardial
infarction Pulmonary: No severe chronic obstructive pulmonary disease Other: No
galactosemia No mental illness or handicap

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
neoadjuvant chemotherapy Endocrine therapy: Not specified Radiotherapy: Not specified
Surgery: See Disease Characteristics At least 1 month since prior core biopsy (Tru-cut) of
breast cancer

Type of Study:

Interventional

Study Design:

Primary Purpose: Diagnostic

Principal Investigator

Gerald Gui, MD, MS, FRCS(Edin), FRCS(Eng)

Investigator Role:

Study Chair

Investigator Affiliation:

Royal Marsden NHS Foundation Trust

Authority:

United States: Federal Government

Study ID:

CDR0000067655

NCT ID:

NCT00005058

Start Date:

August 1997

Completion Date:

Related Keywords:

  • Breast Cancer
  • stage I breast cancer
  • stage II breast cancer
  • stage IIIA breast cancer
  • stage IIIB breast cancer
  • inflammatory breast cancer
  • Breast Neoplasms

Name

Location